Aposense

AposenseA® (formerly NST) is a clinical-stage molecular imaging and drug development company with a range of products based on its patented platform technology for targeting apoptosis (programmed cell death) in vivo. AposenseA® is transforming the science of apoptosis (programmed cell death) into personalized patient care across multiple disease categories, including oncology, cardiology, and neurology.